

DRUG DISCOVERY BIOANALYTICAL SOLUTIONS:

Quick turnarounds for lead optimization

Quick turnarounds during discovery can save you time, money, and work. We understand how responsiveness and quick turnarounds can impact lead optimization for your drug development strategy. Pyxant Labs and ImaBiotech provide technical expertise and solutions so you can select your drug candidate and move on to the next phase with ease and efficiency. Working with us at the start of your project enables:

- 48-hour data delivery for discovery studies*
- Data in the format that is consistent with your processes
- Identification of options and opportunities for molecule advancement
- Access to a variety of simple and complex matrices
- Flexibility to changing or accelerated timeline



48-hour
data delivery
for discovery
studies

Responsiveness and quick turnarounds can help you save money and get to clinic quicker

DISCOVERY	PRE-CLINICAL / CLINICAL	CLINICAL
<ul style="list-style-type: none"> • 48-hour data delivery* 	<ul style="list-style-type: none"> • Initiate method development within 6–8 weeks of proposal • Validation report within 6 weeks 	<ul style="list-style-type: none"> • Support through Phase IV • 3-day data delivery for first-in-human studies • High throughput for large clinical studies

*Small molecule bioanalytical lab projects only; does not include spatial bioanalysis projects

Our specialized discovery team provides support for small molecule, peptides & proteins, and oligonucleotides. Learn how industry experts can take your program from discovery to clinic.

		Phase I	Phase II	Phase III
Pre-sample analysis	Method development	Required		
	Method qualification	Minimal experiments		<ul style="list-style-type: none"> • Freeze-thaw • Bench top • Minimum one accuracy precision run
Review	Adherence to standard operating procedures	No		Yes, with expectations by principal investigator & client approval
	Quality assurance			No
	Quality control	Technical review		Technical review + QC review
Analytical reference material	Analyte characterization requirements	Molecular weight, purity, salt content (if available)		Certificate of analysis (preferred), molecular weight, purity, salt content (if available)
	Internal standard	Small molecule: Generic analog or cocktail Peptides & proteins: Stable label or close chemo type Oligonucleotides: Close chemo type		Small molecule: Labeled compound (preferred) or generic analog Peptides & proteins: Stable label or close chemo type Oligonucleotides: Close chemo type
	Chemical structure	Small molecule: If available Peptides & proteins: FASTA sequence Oligonucleotides: If available, modifications to the sense strand aid delivery and preferred in non-GLP		
	Minimum quantity	Analyte ≥ 2 to 5 mg	Small molecule: Analyte ≥ 2 to 5 mg Peptides & proteins: Analyte ≥ 2 to 5 mg Oligonucleotides: Analyte ≥ 5 mg, internal standard ≥ 5 mg	Small molecule: Analyte ≥ 10 to 50 mg Peptides & proteins: Analyte ≥ 10 to 50 mg Oligonucleotides: Analyte ≥ 10 to 50 mg, internal standard ≥ 10 to 50 mg
	Weighing	Single		Double

		Phase I	Phase II	Phase III
Calibration standards	Concentration range (compound dependent)	Small molecule: 1 to 1000 ng/mL or client defined Peptides & proteins: Client defined Oligonucleotides: 25 to 10,000 ng/mL		Client-defined
	# of standards	As needed		≥ 6 (n=2 front/back)
	Precision & accuracy (compound dependent)	Small molecule: +/- 30% CV and accuracy (+/- 35% LLOQ) Peptides & proteins: +/- 35% CV and accuracy (+/- 40% LLOQ) Oligonucleotides: Biofluid: ≥ 75% of standards within +/- 20% (+/- 25% LLOQ)	Small molecule: +/- 20% CV and accuracy (+/- 25% LLOQ) Peptides & proteins: +/- 25% CV and accuracy (+/- 30% LLOQ) Oligonucleotides: Biofluid: ≥ 75% of standards within +/- 20% (+/- 25% LLOQ)	Small molecule: +/- 15% CV and accuracy (+/- 20% LLOQ) Peptides & proteins: +/- 20% CV and accuracy (+/- 25% LLOQ) Oligonucleotides: ≥ 67% of all QCs within +/- 15%, ≥ 50% at each level pass
QC samples	Concentrations	Up to 3 levels (n=3)		≥ 3 levels (n=3)
	Precision & accuracy	Small molecule: +/- 30% Peptides & proteins: +/- 35% Oligonucleotides: +/- 30%	Small molecule: +/- 20% Peptides & proteins: +/- 25% Oligonucleotides: +/- 20%	Small molecule: +/- 15% Peptides & proteins: +/- 20% Oligonucleotides: +/- 15%
Sample analysis	Turnaround	≤ 5 days from receipt of samples and materials		≤ 10 days from receipt of samples and materials
	Reassays	Extrapolated data provided (requested reassays charged / sample or min. batch rate)		As requested per sample or min. batch rate
	Deliverables	Data table	Data table + summary report (if requested)	Summary report

[Contact us](#) to learn how our discovery team can provide quick turnarounds and lead optimization.